220 related articles for article (PubMed ID: 15566294)
1. Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole.
Pagano MA; Andrzejewska M; Ruzzene M; Sarno S; Cesaro L; Bain J; Elliott M; Meggio F; Kazimierczuk Z; Pinna LA
J Med Chem; 2004 Dec; 47(25):6239-47. PubMed ID: 15566294
[TBL] [Abstract][Full Text] [Related]
2. 2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole: a novel powerful and selective inhibitor of protein kinase CK2.
Pagano MA; Meggio F; Ruzzene M; Andrzejewska M; Kazimierczuk Z; Pinna LA
Biochem Biophys Res Commun; 2004 Sep; 321(4):1040-4. PubMed ID: 15358133
[TBL] [Abstract][Full Text] [Related]
3. Inspecting the structure-activity relationship of protein kinase CK2 inhibitors derived from tetrabromo-benzimidazole.
Battistutta R; Mazzorana M; Sarno S; Kazimierczuk Z; Zanotti G; Pinna LA
Chem Biol; 2005 Nov; 12(11):1211-9. PubMed ID: 16298300
[TBL] [Abstract][Full Text] [Related]
4. Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
Sarno S; de Moliner E; Ruzzene M; Pagano MA; Battistutta R; Bain J; Fabbro D; Schoepfer J; Elliott M; Furet P; Meggio F; Zanotti G; Pinna LA
Biochem J; 2003 Sep; 374(Pt 3):639-46. PubMed ID: 12816539
[TBL] [Abstract][Full Text] [Related]
5. The selectivity of inhibitors of protein kinase CK2: an update.
Pagano MA; Bain J; Kazimierczuk Z; Sarno S; Ruzzene M; Di Maira G; Elliott M; Orzeszko A; Cozza G; Meggio F; Pinna LA
Biochem J; 2008 Nov; 415(3):353-65. PubMed ID: 18588507
[TBL] [Abstract][Full Text] [Related]
6. Development and exploitation of CK2 inhibitors.
Sarno S; Ruzzene M; Frascella P; Pagano MA; Meggio F; Zambon A; Mazzorana M; Di Maira G; Lucchini V; Pinna LA
Mol Cell Biochem; 2005 Jun; 274(1-2):69-76. PubMed ID: 16335530
[TBL] [Abstract][Full Text] [Related]
7. Identification of ellagic acid as potent inhibitor of protein kinase CK2: a successful example of a virtual screening application.
Cozza G; Bonvini P; Zorzi E; Poletto G; Pagano MA; Sarno S; Donella-Deana A; Zagotto G; Rosolen A; Pinna LA; Meggio F; Moro S
J Med Chem; 2006 Apr; 49(8):2363-6. PubMed ID: 16610779
[TBL] [Abstract][Full Text] [Related]
8. Coumarin as attractive casein kinase 2 (CK2) inhibitor scaffold: an integrate approach to elucidate the putative binding motif and explain structure-activity relationships.
Chilin A; Battistutta R; Bortolato A; Cozza G; Zanatta S; Poletto G; Mazzorana M; Zagotto G; Uriarte E; Guiotto A; Pinna LA; Meggio F; Moro S
J Med Chem; 2008 Feb; 51(4):752-9. PubMed ID: 18251491
[TBL] [Abstract][Full Text] [Related]
9. A subnanomolar fluorescent probe for protein kinase CK2 interaction studies.
Enkvist E; Viht K; Bischoff N; Vahter J; Saaver S; Raidaru G; Issinger OG; Niefind K; Uri A
Org Biomol Chem; 2012 Nov; 10(43):8645-53. PubMed ID: 23032938
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of protein kinase CK2 by condensed polyphenolic derivatives. An in vitro and in vivo study.
Meggio F; Pagano MA; Moro S; Zagotto G; Ruzzene M; Sarno S; Cozza G; Bain J; Elliott M; Deana AD; Brunati AM; Pinna LA
Biochemistry; 2004 Oct; 43(40):12931-6. PubMed ID: 15461466
[TBL] [Abstract][Full Text] [Related]
11. Tetraiodobenzimidazoles are potent inhibitors of protein kinase CK2.
Gianoncelli A; Cozza G; Orzeszko A; Meggio F; Kazimierczuk Z; Pinna LA
Bioorg Med Chem; 2009 Oct; 17(20):7281-9. PubMed ID: 19748274
[TBL] [Abstract][Full Text] [Related]
12. Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2.
Cozza G; Mazzorana M; Papinutto E; Bain J; Elliott M; di Maira G; Gianoncelli A; Pagano MA; Sarno S; Ruzzene M; Battistutta R; Meggio F; Moro S; Zagotto G; Pinna LA
Biochem J; 2009 Jul; 421(3):387-95. PubMed ID: 19432557
[TBL] [Abstract][Full Text] [Related]
13. Features and potentials of ATP-site directed CK2 inhibitors.
Sarno S; Salvi M; Battistutta R; Zanotti G; Pinna LA
Biochim Biophys Acta; 2005 Dec; 1754(1-2):263-70. PubMed ID: 16198160
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and proapoptotic properties of new casein kinase II inhibitors.
Koronkiewicz M; Zukowska M; Chilmonczyk Z; Orzeszko A; Kazimierczuk Z
Acta Pol Pharm; 2010; 67(6):635-41. PubMed ID: 21229880
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of new analogs of benzotriazole, benzimidazole and phthalimide--potential inhibitors of human protein kinase CK2.
Najda-Bernatowicz A; Łebska M; Orzeszko A; Kopańska K; Krzywińska E; Muszyńska G; Bretner M
Bioorg Med Chem; 2009 Feb; 17(4):1573-8. PubMed ID: 19168362
[TBL] [Abstract][Full Text] [Related]
16. Quinone reductase 2 is an adventitious target of protein kinase CK2 inhibitors TBBz (TBI) and DMAT.
Leung KK; Shilton BH
Biochemistry; 2015 Jan; 54(1):47-59. PubMed ID: 25379648
[TBL] [Abstract][Full Text] [Related]
17. Urolithin as a converging scaffold linking ellagic acid and coumarin analogues: design of potent protein kinase CK2 inhibitors.
Cozza G; Gianoncelli A; Bonvini P; Zorzi E; Pasquale R; Rosolen A; Pinna LA; Meggio F; Zagotto G; Moro S
ChemMedChem; 2011 Dec; 6(12):2273-86. PubMed ID: 21972104
[TBL] [Abstract][Full Text] [Related]
18. Protein kinase CK2 as a druggable target.
Sarno S; Pinna LA
Mol Biosyst; 2008 Sep; 4(9):889-94. PubMed ID: 18704226
[TBL] [Abstract][Full Text] [Related]
19. Protein kinase CK2 catalyzes tyrosine phosphorylation in mammalian cells.
Vilk G; Weber JE; Turowec JP; Duncan JS; Wu C; Derksen DR; Zien P; Sarno S; Donella-Deana A; Lajoie G; Pinna LA; Li SS; Litchfield DW
Cell Signal; 2008 Nov; 20(11):1942-51. PubMed ID: 18662771
[TBL] [Abstract][Full Text] [Related]
20. Protein kinase CK2 interacts with adiponectin receptor 1 and participates in adiponectin signaling.
Heiker JT; Wottawah CM; Juhl C; Kosel D; Mörl K; Beck-Sickinger AG
Cell Signal; 2009 Jun; 21(6):936-42. PubMed ID: 19233263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
